S 1425
117th Congress
Senate
Health
Administrative remedies
Business ethics
Civil actions and liability
Competition and antitrust
Department of Health and Human Services
Drug safety, medical device, and laboratory regulation
Food and Drug Administration (FDA)
Licensing and registrations
Prescription drugs
Public participation and lobbying
Stop STALLING Act
Everywhere this bill has been
5 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Dec 8, 2021
Placed on Senate Legislative Calendar under General Orders. Calendar No. 179.
Dec 8, 2021
Committee on the Judiciary. Reported by Senator Durbin without amendment. Without written report.
Jul 29, 2021
Committee on the Judiciary. Ordered to be reported without amendment favorably.
Apr 28, 2021
Read twice and referred to the Committee on the Judiciary.
Apr 28, 2021
Introduced in Senate
Plain-English summary
Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act
This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.
The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit shall be subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.
What's happening now
Placed on Senate Legislative Calendar under General Orders. Calendar No. 179.
Committees of jurisdiction
1